孟鲁司特亚砜 | 909849-96-3

• 物质功能分类: 化学试剂 - 有机试剂 - 砜、亚砜类化合物
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 中文名称: 孟鲁司特亚砜
• 中文别名: 孟鲁斯特亚砜；孟鲁司特钠亚砜；孟鲁司特钠杂质C
• 英文名称: 2-[1-[[1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfinylmethyl]cyclopropyl]acetic acid
• CAS: 909849-96-3
• 化学式: C₃₅H₃₆ClNO₄S
• 分子量: 602.2
• InChiKey: QFTNWCBEAVHLQA-XNTDXEJSSA-N

物化性质

• 熔点：
  95-97°C
• 沸点：
  818.5±65.0 °C(Predicted)
• 密度：
  1.319
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  42
• 可旋转键数：
  12
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  107
• 氢给体数：
  2
• 氢受体数：
  6

制备方法与用途

用途

孟鲁司特亚砜(孟鲁司特EP杂质C;孟鲁司特USP相关化合物A;亚砜孟鲁司特)是孟鲁司特的代谢物。用作杂质标准品、对照品。

文献信息

• ORAL PHARMACEUTICAL FORMULATION OF MONTELUKAST AND LEVOCETIRIZINE AND METHOD FOR ITS PRODUCTION
  申请人：Invest Bielany Spolka z ograniczona odpowiedzialnoscia

  公开号：EP3222279B1

  公开（公告）日：2021-11-17
• LIQUID FORMULATION COMPRISING MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METHOD FOR PREPARING SAME
  申请人：HANMI PHARM. CO., LTD.

  公开号：US20170157108A1

  公开（公告）日：2017-06-08

  The present invention relates to a liquid formulation comprising a solubilizer and montelukast or pharmaceutically acceptable salt thereof in a solution state as an active ingredient, and a method for preparing same. The liquid formulation of the present invention allows montelukast or pharmaceutically acceptable salt thereof to be substantially dissolved and present in a solution state, thereby preventing decrease of dissolution over time and increasing its bioavailability. In addition, because the liquid formulation of the present invention shows superior stability, taste and flavor, its medication compliance can be enhanced, and it can be effectively utilized for asthma and allergic rhinitis patients.
• [EN] LIQUID FORMULATION WITH ENHANCED STABILITY COMPRISING MONTELUKAST OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND METHOD FOR PREPARING SAME<br/>[FR] PRÉPARATION LIQUIDE PLUS STABLE COMPRENANT DU MONTÉLUKAST OU UN SEL DE MONTÉLUKAST PHARMACEUTIQUEMENT ACCEPTABLE, ET PROCÉDÉ DE PRÉPARATION ASSOCIÉ
  申请人：HANMI PHARM IND CO LTD

  公开号：WO2015170835A1

  公开（公告）日：2015-11-12

  The present invention relates to a liquid formulation comprising an electrolyte compound, and montelukast or a pharmaceutically acceptable salt thereof as an active ingredient, and a method for preparing the above liquid formulation. According to the present invention, montelukast or a pharmaceutically acceptable salt thereof is substantially dissolved and present in a solution state, thereby improving stability over time, preventing decrease of dissolution and stability over time and increasing its bioavailability. And, owing to its enhanced stability and superior taste and flavor, the liquid formulation of the present invention shows improved medication compliance, and can be effectively used for the treatment of asthma and allergic rhinitis.